Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,358,366

« Back to Dashboard
Patent 7,358,366 protects AVANDARYL, AVANDAMET, and AVANDIA, and is included in three NDAs. There have been zero Paragraph IV challenges on Avandaryl and There are six tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for AVANDARYL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 7,358,366

Title:Thiazolidinedione derivative and its use as antidiabetic
Abstract:A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione- , maleic acid salt (the "Polymorph") characterised in that it provides: (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602 cm.sup.-1; and/or (ii) a Raman spectrum containing peaks at 1751, 1243 and 602 cm.sup.-1; and/or (iii) a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 172.0, and 175.0 ppm; and/or (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.
Inventor(s): Blackler; Paul David James (Cadiz, ES), Giles; Robert Gordon (Tonbridge, GB), Moore; Stephen (Tonbridge, GB), Sasse; Michael John (Tonbridge, GB)
Assignee: SmithKline Beecham p.l.c. (Brentford, Middlesex, GB)
Application Number:11/458,471
Patent Claim Types:
see list of patent claims
Patent Metrics:
Source: PatentQuant.com
Field: Organic fine chemistry
Back Citations: 20th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sb Pharmco
glimepiride; rosiglitazone maleate
TABLET;ORAL021700-001Nov 23, 2005DISCNNo7,358,366*PEDOct 19, 2020Y
Sb Pharmco
glimepiride; rosiglitazone maleate
TABLET;ORAL021700-002Nov 23, 2005DISCNNo7,358,366*PEDOct 19, 2020Y
Sb Pharmco
glimepiride; rosiglitazone maleate
TABLET;ORAL021700-004Mar 30, 2007DISCNNo7,358,366*PEDOct 19, 2020Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: 7,358,366

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
7,358,366 April 15, 2012

Foreign Priority and PCT Information for Patent: 7,358,366

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9909471.6Apr 23, 1999
United Kingdom9912195.6May 25, 1999

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.